CClinicalTrials.gg
CompletedNCT02555410Updated Jul 12, 2017

Seizure Detection and Warning System in Epilepsy Patients

An observational study in Epilepsy and Generalized Tonic-Clonic Seizures, sponsored by Brain Sentinel. Completed at 1 site in United States. Open to participants aged 2 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-07-12.

Sponsored by Brain Sentinel · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11
Ages
2 Years to 99 Years
Sex
All
01

Study summary

This is a phase III, pilot, prospective study of an Electromyography (EMG) based seizure detection system for detecting Generalized Tonic-Clonic Seizures (GTCS) in the home.

Read the detailed description

The Brain Sentinel™ Seizure Detection and Warning System is intended for monitoring children and adults with a history or significant risk of generalized tonic-clonic seizures in the home or healthcare facilities, during the titration or withdrawal of anti-epileptic drugs, and for continuous monitoring (night time or any other time of day) of individuals due to their history or risk of generalized tonic-clonic seizures. The device will withstand activities of daily living including showers and sleep.

02

Conditions studied

  • Epilepsy
  • Generalized Tonic-Clonic Seizures
03

In context

Epilepsy

1,806 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

This study's enrollment of 11 is below the median of 102 across 521 observational studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Brain Sentinel is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization

Inclusion criteria

  1. Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization.
  2. Male or female between the ages of 2-99.
  3. Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm).
  4. Be able to tolerate wearing the device on the upper arm.
  5. If female and of childbearing potential, has a negative pregnancy test.
  6. Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.
  7. Subject and/or Primary Caregiver must be competent to follow all study procedures.
  8. Is able to read, speak and understand English.

Exclusion criteria

Exclusion Criteria:

  1. Does not have a documented history of generalized seizures.
  2. The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm)
  3. Pregnant female
  4. Subject/Caregiver is unable to provide consent.
  5. Subject/Caregiver is not competent to follow home study procedures.
  6. The subject is homeless or in a home without a power supply.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11 participants (actual)
Patient registry
No

Groups and cohorts

  • Brain Sentinel Seizure Detection and Warning System

    To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.

    Device: Brain Sentinel Seizure Detection and Warning System

Interventions

  • DeviceBrain Sentinel Seizure Detection and Warning System

    A sEMG based automated seizure detection and warning system worn on the biceps

    Also known as: SPEAC System

06

What researchers measure

Primary outcomes

  1. Test the function of the system including ability to acquire EMG signal, analyze and successfully transmit the analysis to the base station, and identify and transmit all alert conditions.

    The overall usability and technical features will be assessed through questionnaires and surveys as the Seizure Detection and Warning System will be used within a home setting.

    Time frame: up to 1 month

Secondary outcomes

  1. Compare the accuracy of the EMG based system's log to the subject's seizure diary

    Comparison of the subject's seizure diary to the EMG based seizure detection system's seizure logs will help determine overall function.

    Time frame: up to one month

07

Study locations

1 site
  • Jose' E. Cavazos
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02555410
Lead sponsor
Brain Sentinel
Responsible party
Sponsor
First posted
Sep 21, 2015
Start date
Jan 2013
Primary completion
Jul 7, 2017
Completion
Jul 7, 2017
Last update
Jul 12, 2017

Study contacts

Jose E. Cavazos, MD, PhD
principal investigator · Brain Sentinel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion